5244702026-01-012026-03-315244702026-03-315244702025-03-315244702025-04-012026-03-315244702026-01-012026-03-31in-capmkt:OtherExpenses1Member5244702025-04-012026-03-31in-capmkt:OtherExpenses1Member5244702026-03-31OtherNoncurrentFinancialAssetsDomain15244702026-03-31OtherNoncurrentFinancialAssetsDomain25244702026-03-31OtherNoncurrentAssetsDomain15244702026-03-31OtherCurrentFinancialAssetsDomain15244702026-03-31OtherCurrentAssetsDomain15244702026-03-31OtherNoncurrentFinancialLiabilitiesDomain15244702026-03-31OtherNoncurrentLiabilitiesDomain15244702026-03-31OtherCurrentFinancialLiabilitiesDomain15244702026-03-31OtherCurrentLiabilitiesDomain15244702026-01-012026-03-31in-capmkt:ReportableSegments1Member5244702026-01-012026-03-31in-capmkt:ReportableSegments2Member5244702026-01-012026-03-31in-capmkt:ReportableSegments3Member5244702025-04-012026-03-31in-capmkt:ReportableSegments1Member5244702025-04-012026-03-31in-capmkt:ReportableSegments2Member5244702025-04-012026-03-31in-capmkt:ReportableSegments3Member5244702026-01-012026-03-31in-capmkt:ReportableSegments1Member5244702026-01-012026-03-31in-capmkt:ReportableSegments2Member5244702026-01-012026-03-31in-capmkt:ReportableSegments3Member5244702025-04-012026-03-31in-capmkt:ReportableSegments1Member5244702025-04-012026-03-31in-capmkt:ReportableSegments2Member5244702025-04-012026-03-31in-capmkt:ReportableSegments3Member5244702026-01-012026-03-31in-capmkt:ReportableSegments1Member5244702026-03-31in-capmkt:ReportableSegments1Member5244702026-01-012026-03-31in-capmkt:ReportableSegments2Member5244702026-03-31in-capmkt:ReportableSegments2Member5244702026-01-012026-03-31in-capmkt:ReportableSegments3Member5244702026-03-31in-capmkt:ReportableSegments3Member5244702026-01-012026-03-31in-capmkt:ReportableSegments1Member5244702026-03-31in-capmkt:ReportableSegments1Member5244702026-01-012026-03-31in-capmkt:ReportableSegments2Member5244702026-03-31in-capmkt:ReportableSegments2Member5244702026-01-012026-03-31in-capmkt:ReportableSegments3Member5244702026-03-31in-capmkt:ReportableSegments3Member5244702026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15244702025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15244702026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524470SYNCOMFNOTLISTEDINE312C01025Syncom Formulations (India) LimitedMain BoardEquity2025-04-012026-03-312026-05-222026-05-13INRLakhsQuarterlyFourth quarterMulti segment2026-05-2215:00:002026-05-2218:15:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated13541180001455380001499656000674484000205453000-468210001694730003759000248230001314150001162586000337070000-4400033702600074070000112120008528200002517440000000251744000-99517000152227000000094000000010.270.27000.270.272025-04-012026-03-31AuditedConsolidated489171500031339900052051140002209368000672287000-3893000067085100011550000653230006038390004194288000101082600036900010111950002286730001814200024681500007643800000000764380000-360730007283070000000940000000132098830000.810.81000.810.81OTHER EXPENCES131415000OTHER EXPENCES60383900089766600009334670000397200000025343000001612350001865780001311500020347980006287850001065164000110504800051475000119120007039300038148000234214000033272900033036540005338452000940000000320988300041498830004149883000000015765000157650005411700081247000018200015131100014742000586780006852240007439020002154800078019200019285800064208000103725800011885690005338452000Fixed Deposits and accured Interest154145000Deposits7090000Other non-current assets13115000Deposits38148000Other current assets332729000other non-current financial liabilities15765000Other non-current liabilities182000Other current financial liabilities21548000Other current liabilities192858000Pharmaceuticals Drugs & Formulations1490049000Trading of Commodities403000Renting of Property9204000Pharmaceuticals Drugs & Formulations5157338000Trading of Commodities11003000Renting of Property36773000149965600052051140000014996560005205114000Pharmaceuticals Drugs & Formulations337166000Trading of Commodities-435000Renting of Property4054000Pharmaceuticals Drugs & Formulations993187000Trading of Commodities-263000Renting of Property298210003407850001022745000375900011550000003370260001011195000Pharmaceuticals Drugs & Formulations4397601000Trading of Commodities6651000Renting of Property934200000533845200005338452000Pharmaceuticals Drugs & Formulations1171350000Trading of Commodities412000Renting of Property16807000118856900001188569000Notes:- <BR> 1. The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 22/05/2026 <BR> 2. These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time. <BR> 3. The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required. <BR> 4. The Consolidated Statement of Assets and Liabilities as at 31st March, 2026 and the Consolidated Statement of Cash Flow is provided as an annexure to this statement. <BR> 5.As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the Auditor’s report provided by the Statutory Auditors have carried out Audit books of Accounts for the Financial year 2025-2026 and issued us an Audit Report with an unmodified opinion on Audited financial Results for the Quarter / Year ended 31st March, 2026 Therefor the company is not required to give statement of Impact of Audit Qualification for Audit report with modified opinion <BR> 6.Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification. <BR> 7.The figures of the Last Quarter are the balancing figures between the audited figures in respect of full financial year & the published year to date figures upto 3rd quarter of that financial year <BR> 8. The Company currently have 3 (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd, Sante Biotech Pvt. Ltd And Vincit Biotech International Pvt. Ltd. <BR> 9. The Government of India has notified four Labour Codes -namely the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 - with effect from 21 November 2025, which consolidates 29 existing labour laws. The Ministry of Labour & Employment has published draft Central Rules and FAQs on these codes, but the relevant rules are yet to be notified. Based on the available information , The Company has assessed the implications of the New Labour Codes and has recognized an incremental cost of, 87.81 Lacs during the year ended March 31, 2026. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, <BR> 10. During the current period, the Company has corrected its method of calculating Earnings Per Share (EPS). In previous years/Quarters, EPS was calculated considering Total Comprehensive Income. To comply with the requirements of Ind AS 33, the EPS has now been computed using Profit After Tax attributable to equity shareholders. Consequently, the comparative EPS for all preceding periods has been restated. There is no restatement in any line items only EPS is restated. The Figurs as Previously reported and restated are as below <BR> <BR> Previously Reported EPS (TCI) Quarter Ended Year Ended <BR> 31-03-2026 31-12-2025 31-03-2025 31-03-2026 31-03-2025 <BR> Audited Unaudited Audited Audited Audited <BR> Earnings per equity share (for discontinued & continuing operations) <BR> (1) Basic NA 0.23 0.16 NA 0.57 <BR> (2) Diluted NA 0.23 0.16 NA 0.57 <BR> Restated EPS (PAT)) <BR> Earnings per equity share (for discontinued & continuing operations) <BR> (1) Basic 0.27 0.20 0.19 0.81 0.53 <BR> (2) Diluted 0.27 0.20 0.19 0.81 0.53 <BR> 11550000-215465000-295630000-11364300000-16040000030258500001500390000-9206000022373000043000000000000-30478900000-20172900080946600000022867300005807930000000000001166990000199217000000000000000000000-190311000-50622700000000000-3109400000011550000012433000-302110004435500004435500071200005147500000ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS-99517000-99517000ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS-36073000-3607300000-99517000-36073000AuditedtrueSanjay Mehta And Associates, Chartered Accountantstrue2027-03-31